Radiolabels

Radiolabels are radioactive atoms or molecules attached to another chemical entity to enable detection and tracking by measuring emitted radiation. They are used to study how substances distribute within biological systems, how they are metabolized, and how they interact with targets such as receptors. In medicine, radiolabels underpin diagnostic imaging and targeted radiotherapy.

Labeling methods fall into direct and indirect approaches. Direct labeling attaches the radioisotope to the molecule itself, often by substituting a reactive site or through isotope exchange. Indirect labeling uses a chelator or prosthetic group that binds the radioisotope and is then linked to the target. The choice depends on stability, labeling efficiency, and biological properties. Common isotopes include gamma emitters for SPECT (technetium-99m, indium-111); positron emitters for PET (fluorine-18, gallium-68, copper-64, zirconium-89); and therapeutic isotopes such as lutetium-177, yttrium-90, and iodine-131. Chelators like DOTA and DTPA and prosthetic groups such as NHS-esters or isothiocyanates enable labeling; emerging methods include bioorthogonal chemistry for site-specific attachment.

Applications include clinical imaging, such as 18F-FDG PET to assess metabolic activity, and 99mTc- or 111In-labeled tracers for SPECT imaging, as well as radiolabeled antibodies and peptides for targeted imaging. Radiopharmaceuticals are also used in therapy, exemplified by 177Lu-DOTATATE for neuroendocrine tumors or 131I for thyroid treatment. In research, radiolabels support autoradiography and pharmacokinetic studies.

Quality and safety considerations encompass radiochemical purity, specific activity, stability, sterility, and absence of pyrogens, together with regulatory compliance for handling, storage, and waste. Radiation exposure safeguards and standardized manufacturing practices are essential throughout the lifecycle of radiolabeled agents.

Historically, the discovery of radioactivity by Becquerel and the Curies opened the field; Technetium-99m became the workhorse for medical imaging in the 1960s, spurring rapid development of radiopharmaceuticals and imaging modalities such as PET and SPECT.